In fact, a study showed that the immunoselection of human BC cell lines with trastuzumab and polyclonal NK cells promoted the preferential survival of the CD44highCD24low population, which expresses lower levels of HER2 [124]. The gene discussed is ERBB2; the disease is breast cancer.